D-二聚体和FDPs联合检测在血栓性疾病中的应用  

Discussing of D-dimer and FDPs combined application in detection of thrombotic diseases

作　　者：桂艺方[1] 张春雷[2] 韩伟平[3] 

机构地区：[1]牡丹江医学院红旗医院检验科,黑龙江牡丹江157011 [2]牡丹江医学院医药研究中心,黑龙江牡丹江157011 [3]大连医科大学附属第二医院检验科,辽宁大连116027

出　　处：《大连医科大学学报》2012年第1期78-80,100,共4页Journal of Dalian Medical University

摘　　要：[目的]探讨D-二聚体和纤维蛋白(原)降解产物(FDPs)联合应用在血栓性疾病检测中的意义。[方法]选择2010—2011年住院患者60例,基础疾病为肺梗死、深静脉血栓,均为发病初期;另选择同时期门诊患者30例,基础疾病为非血栓性疾病。采用免疫比浊法测定D-二聚体浓度和FDPs浓度,观察两项指标的检测结果对疾病检测的敏感性。[结果]D-二聚体在肺梗死、深静脉血栓和非血栓性疾病中的阳性检出率分别是93.3%、86.7%和3.3%;FDPs在肺梗死、深静脉血栓和非血栓性疾病中的阳性检出率分别是100%、96.7%、40.0%;D-二聚体和FDP s联合检测在肺梗死、深静脉血栓和非血栓性疾病中的阳性检出率分别是100%、96.7%和3.3%。两项指标联合检测与D-二聚体、FDPs单独检测差异有显著性意义(P<0.01)。[结论]D-二聚体和FDPs联合检测较二者单独检测意义更大,能够明显的避免漏检及假阳性结果的产生,能够更加准确地为临床提供阳性数据及排除阴性疾病。[Objective]In combined application of D-dimer and FDPS in the test of the thrombotic disease.[Methods]Sixty hospitalized patients from 2010 to 2011 were selected for the research,whose underlying disease was early stage pulmonary infarction and deep vein thrombosis.The other 30 outpatients were selected from 2010 to 2011,whose underlying disease was non thrombotic disease.ITM immunoturbidimetry was employed to determine the density of D-dimer and FDPs.[Results]The positive rate of D-dimer in pulmonary infarction,deep vein thrombosis and the non thrombotic diseases was 93.3%,86.7% and 3.3% respectively.FDPs positive rate in pulmonary infarction,deep vein thrombosis and the non thrombotic diseases was 100%,96.7%,40.0% respectively.The positive rate of both D-dimer and FDPs in pulmonary infarction,deep vein thrombosis and the non thrombotic diseases was 100%,96.7% and 3.3% respectively.The combined measuring results had significant differences compared with D-Dimer and FDPs seperately（P0.01）.[Conclusions]Combined testing of D-dimer and FDPs is more significant than separate testing that can avoid omission and false positive result.Meanwhile it also provides positive data more accurately and excludes negative disease.

关 键 词：血栓性疾病 D-二聚体 FDPs 联合检测 

分 类 号：R446.6[医药卫生—诊断学]